Cart
sales@molnova.com
2'-Deoxy-2'-fluorouridine
CAS No. 784-71-4
2'-Deoxy-2'-fluorouridine( —— )
Catalog No. M28166 CAS No. 784-71-4
2'-Deoxy-2'-fluorouridine is an antiinfluenza virus agents synthesis intermediate.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 37 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2'-Deoxy-2'-fluorouridine
-
NoteResearch use only, not for human use.
-
Brief Description2'-Deoxy-2'-fluorouridine is an antiinfluenza virus agents synthesis intermediate.
-
Description2'-Deoxy-2'-fluorouridine is an antiinfluenza virus agents synthesis intermediate.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorBD1-BRD4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number784-71-4
-
Formula Weight246.194
-
Molecular FormulaC9H11FN2O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (406.19 mM)
-
SMILESOC[C@H]1O[C@H]([C@H](F)[C@@H]1O)n1ccc(=O)[nH]c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liu Z, et al. Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site. J Med Chem. 2022;65(3):2388-2408.
molnova catalog
related products
-
Procyanidin C2
Procyanidin C2 is a phenol glycoside derived from Fagopyrum dibotrys (D. Don) Hara.
-
BDC2.5 mimotope 1040...
This is a effectively agonistic peptide (mimotope) for diabetogenic T cell clone BDC2.5. It can stimulate BDC2.5 cells with cells showing good response to this mimotope. 1040-31 peptide is specific for BDC2.5 TCR Tg+ (transgenic) T cells. This peptide is also known as p31.
-
MAGE-A3 195-203
This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.
